Reduced paraoxonase 1 activity as a marker for severe coronary artery disease

Disease Markers

Volumn 35, Issue 2, 2013, Pages 97-103

  Zhou, Chiyan ^a   Cao, Jia ^a   Shang, Liang ^a   Tong, Chuanfeng ^b   Hu, Hanling ^b   Wang, Hui ^a   Fan, Daping ^c   Yu, Hong ^a  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHEMICAL PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENSINI SCORE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

MUS;

AGED; ANIMALS; AORTA; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84882303543     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/816189     Document Type: Article

References (36)

1. G. K. Hansson, "Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease, " The New England Journal of Medicine, vol. 352, no. 16, pp. 1685-1695, 2005.
2. N. R. Madamanchi, A. Vendrov, and M. S. Runge, "Oxidative stress and vascular disease, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 1, pp. 29-38, 2005.
3. F. Tabet and K.-A. Rye, "High-density lipoproteins, inflammation and oxidative stress, " Clinical Science, vol. 116, no. 2, pp. 87- 98, 2009.
4. G. S. Getz and C. A. Reardon, "Paraoxonase, a cardioprotective enzyme: continuing issues, " Current Opinion in Lipidology, vol. 15, no. 3, pp. 261-267, 2004.
5. B. MacKness and M. MacKness, "Anti-inflammatory properties of paraoxonase-1 in atherosclerosis, " Advances in Experimental Medicine and Biology, vol. 660, pp. 143-151, 2010.
6. D. M. Shih, Y.-R. Xia, X.-P. Wang et al., "Combined serum paraoxonase knockout/apolipoprotein E knockoutmice exhibit increased lipoprotein oxidation and atherosclerosis, " Journal of Biological Chemistry, vol. 275, no. 23, pp. 17527-17535, 2000.
7. D. S. Ng, T. Chu, B. Esposito, P. Hui, P. W. Connelly, and P. L. Gross, "Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia, " Cardiovascular Pathology, vol. 17, no. 4, pp. 226-232, 2008.
8. A. Tward, Y.-R. Xia, X.-P. Wang et al., "Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice, " Circulation, vol. 106, no. 4, pp. 484-490, 2002.
9. B. MacKness, R. Quarck, W. Verreth, M. MacKness, and P. Holvoet, "Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1545-1550, 2006.
10. M.Wang, X. Lang, S. Cui et al., "Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk, " DNA and Cell Biology, vol. 31, pp. 975-982, 2012.
11. Y. Zhao, Y. Ma, Y. Fang et al., "Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies, " Molecular Genetics and Metabolism, vol. 105, no. 1, pp. 141-148, 2012.
12. Z. Tartan, G. Orhan, H. Kasikcioglu et al., "The role of paraoxonase (PON) enzyme in the extent and severity of the coronary artery disease in type-2 diabetic patients, " Heart and Vessels, vol. 22, no. 3, pp. 158-164, 2007.
13. A. Balcerzyk, I. Zak, and J. Krauze, "Protective effect of R allele of PON1 gene on the coronary artery disease in the presence of specific genetic background, " DiseaseMarkers, vol. 24, no. 2, pp. 81-88, 2008.
14. B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr et al., "Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: The Coronary Artery Risk Development inYoungAdults (CARDIA) study, " Clinical Chemistry, vol. 54, no. 4, pp. 738-746, 2008.
15. G. G. Gensini, "A more meaningful scoring system for determining the severity of coronary heart disease, " American Journal of Cardiology, vol. 51, no. 3, p. 606, 1983.
16. K.Handa, S.Kono, K. Saku et al., "Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis, " Atherosclerosis, vol. 77, no. 2-3, pp. 209-213, 1989.
17. H. Yu, W. Zhang, P. G. Yancey et al., "Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI doubleknockout mice, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 150-156, 2006.
18. V. G. Cabana, C. A. Reardon, N. Feng, S.Neath, J. Lukens, and G. S. Getz, "Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response, " Journal of Lipid Research, vol. 44, no. 4, pp. 780-792, 2003.
19. J. Perla-Kajan and H. Jakubowski, "Paraoxonase 1 and homocysteine metabolism, " Amino Acids, vol. 43, no. 4, pp. 1405-1417, 2012.
20. A. S. Plump, J. D. Smith, T. Hayek et al., "Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells, " Cell, vol. 71, no. 2, pp. 343-353, 1992.
21. S. H. Zhang, R. L. Reddick, J. A. Piedrahita, and N. Maeda, "Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E, " Science, vol. 258, no. 5081, pp. 468- 471, 1992.
22. K. R. Feingold, R. A. Memon, A. H. Moser, and C. Grunfeld, "Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response, " Atherosclerosis, vol. 139, no. 2, pp. 307-315, 1998.
23. J. Kotur-Stevuljevic, S. Spasic, Z. Jelic-Ivanovic et al., "PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients, " Clinical Biochemistry, vol. 41, no. 13, pp. 1067-1073, 2008.
24. M. Miller, N. J. Stone, C. Ballantyne et al., "Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association, " Circulation, vol. 123, no. 20, pp. 2292-2333, 2011.
25. D. L. Rainwater, S. Rutherford, T. D. Dyer et al., "Determinants of variation in human serum paraoxonase activity, " Heredity, vol. 102, no. 2, pp. 147-154, 2009.
26. M.-C. Blatter Garin, X.Moren, and R.W. James, "Paraoxonase- 1 and serum concentrations of HDL-cholesterol and apoA-I, " Journal of Lipid Research, vol. 47, no. 3, pp. 515-520, 2006.
27. L. S. Rozek, T. S. Hatsukami, R. J. Richter et al., "The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status, " Journal of Lipid Research, vol. 46, no. 9, pp. 1888-1895, 2005.
28. P. D. Sarkar, T. M. Shivaprakash, and B. Madhusudhan, "Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease, " Clinica Chimica Acta, vol. 373, no. 1-2, pp. 77-81, 2006.
29. A. Kontush and M. J. Chapman, "Functionally defective highdensity lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis, " Pharmacological Reviews, vol. 58, no. 3, pp. 342-374, 2006.
30. M. Navab, S. T. Reddy, B. J. van Lenten, and A. M. Fogelman, "HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms, " Nature Reviews Cardiology, vol. 8, no. 4, pp. 222-232, 2011.
31. Y. Zhao, R. Wang, X. Ma et al., "Distribution of C-reactive protein and its association with cardiovascular risk factors in a population-based sample of Chinese, " Disease Markers, vol. 28, no. 6, pp. 333-342, 2010.
32. N. Sarwar, A. J. Thompson, and E. Di Angelantonio, "Markers of inflammation and risk of coronary heart disease, " Disease Markers, vol. 26, no. 5-6, pp. 217-225, 2009.
33. B.MacKness, D. Hine, P.McElduff, andM.MacKness, "High Creactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease, " Atherosclerosis, vol. 186, no. 2, pp. 396-401, 2006.
34. C. Mineo and P. W. Shaul, "PON-dering differences in HDL function in coronary artery disease, " Journal of Clinical Investigation, vol. 121, no. 7, pp. 2545-2548, 2011.
35. B. Fuhrman, A. Gantman, and M. Aviram, "Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis, " Atherosclerosis, vol. 211, no. 1, pp. 61-68, 2010.
36. C. Besler, K.Heinrich, L. Rohrer et al., "Mechanisms underlying adverse effects ofHDL on eNOS-activating pathways in patients with coronary artery disease, " Journal of Clinical Investigation, vol. 121, no. 7, pp. 2693-2708, 2011.